Tectonic Therapeutic, Inc.

NASDAQ:TECX

Biotechnology

Healthcare
$21.04 -0.96%

-$0.29 today

Market cap
$411.32M
Beta
1.22
P/E (TTM)
-6.7
EPS (TTM)
-$4.45
52W Low $14.39High $36.03

Volume 0.17M

Average 0.20M

TECX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Tectonic Therapeutic, Inc.NASDAQ: TECX

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How TECX compares with its peers on the latest reported figures

  • TECX's LTM Mar 2026 revenue of $0 is the 3rd highest of the 4 companies compared; the peer median is $31.89M.
TECX Competitors Peer median
Revenue for TECX and competitors
Company Period LTM YoY 3-year CAGR
SEPNSepterna, Inc.LTM Sep 2026$96.27M +336.7%—
GENBGenerate Biomedicines, Inc.FY2025$31.89M +55.9%—
TECXTectonic Therapeutic, Inc.LTM Mar 2026$0 ——
GPCRStructure Therapeutics Inc.LTM Jun 2026$0 ——
Peer median (excluding TECX) $31.89M+196.3%—

Competitors are the stored peer set for TECX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development10.98M25.65M36.97M41.36M63.49M
Selling, General & Admin4.63M7.18M7.68M16.65M20.55M
Operating Expenses15.61M32.83M44.65M58.02M84.04M
Depreciation & Amortization364K1.01M1.48M1.65M1.38M
EBITDA(8.12M)(31.03M)(41.19M)(56.23M)(71.48M)
EBITDA Margin—————
Operating Income(15.61M)(32.83M)(44.65M)(58.02M)(84.04M)
Operating Margin—————
Interest Income0149K581K4.26M11.3M
Interest Expense224K144K152K107K63K
Other Income / Expenses6.68M650K1.83M33K11.12M
Income Before Tax(8.93M)(32.18M)(42.82M)(57.98M)(72.92M)
Pre-Tax Margin—————
Income Tax Expense00001.23M
Net Income(8.93M)(32.18M)(42.82M)(57.98M)(74.15M)
Net Margin—————
EPS (Basic)(33.36)(29.05)(11.59)(3.93)(4.05)
EPS (Diluted)(33.36)(29.05)(11.53)(3.93)(4.05)
Weighted Avg Shares3.57M3.64M3.69M14.77M18.32M
Weighted Avg Shares (Diluted)3.57M3.64M3.71M14.77M18.32M

Tectonic Therapeutic, Inc.

NASDAQ:TECX

Intrinsic Alpha fair value

Locked

Current Price

$21.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.